August 13, 2020
Jeffrey Guss, Robert Krause, Jordan Sloshower
86 citations
preprint
The Yale Manual for Psilocybin-Assisted Therapy of Depression offers researchers and therapists a detailed guide on methods, structure, and considerations for using psychedelic-assisted therapy to treat Major Depressive Disorder. It specifically demonstrates how Acceptance and Commitment Therapy (ACT) can serve as a therapeutic framework for psilocybin-assisted depression treatment.
Scientific reports
April 17, 2024
Jordan Sloshower, Richard J Zeifman, Jeffrey Guss et al.
56 citations
Psilocybin-assisted therapy improves psychological flexibility, mindfulness, and values-congruent living in people with moderate to severe major depressive disorder, and these improvements are strongly linked to reductions in depression severity. In an exploratory placebo-controlled study, participants received placebo then psilocybin (0.3 mg/kg) four weeks later, with dosing sessions embedded in Acceptance and Commitment Therapy. Psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved after psilocybin and were maintained through week 16. The findings suggest that increasing psychological flexibility may be a key mechanism underlying psilocybin's therapeutic effects.
November 15, 2022
Jeffrey Guss, Robert Krause, Jordan Sloshower
preprint
This document is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. It provides researchers and therapists with methods, structure, and considerations for using psychedelic-assisted therapy to treat major depressive disorder. Specifically, the manual illustrates how Acceptance and Commitment Therapy (ACT) can serve as the therapeutic framework for psilocybin-assisted depression treatment.
Clinical Case Studies
August 1, 2021
Mailae Halstead, Sara Reed, Robert Krause et al.
A client with treatment-resistant PTSD stemming from racism and childhood sexual abuse showed significant symptom reduction after four ketamine administrations over 13 days combined with mindfulness-based cognitive therapy and functional analytic psychotherapy. Gains were maintained at a 4-month follow-up. The case demonstrates ketamine as an effective adjunct to psychotherapy for treatment-resistant PTSD.